Citations

Clear

7551 citation(s) found for "Ho, Matthew".

IC‐P‐180: PET TAU Imaging With AV‐1451 in Microtubule Associated Protein TAU (MAPT) Mutation Carriers Relative to Alzheimer’s Disease Dementia and Controls
Lowe, Val J. , Wiste, Heather J. , Dheel, Christina, Rademakers, Rosa , Petersen, Ronald C. , Boeve, Bradley F. , Jones, David T. , Senjem, Matthew L. , Kantarci, Kejal , Knopman, David S. , Wszołek, Zbigniew K. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2016.06.211 Get It

P1‐270: AV‐1451 TAU‐PET in Clinical Variants of Progressive Supranuclear Palsy
Josephs, Keith A. , Whitwell, Jennifer L. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Lowe, Val J. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2016.06.1020 Get It

IC‐P‐201: Predicting Amyloid Deposition in Progressive Aphasia and Apraxia of Speech Using Clinical and Mri Data
Whitwell, Jennifer L. , Weigand, Stephen D. , Gunter, Jeffrey L. , Lowe, Val J. , Josephs, Keith A. , Duffy, Joseph R. , Strand, Edythe A. , Machulda, Mary M. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2016.06.233 Get It

IC‐P‐197: Regional TAU‐PET Uptake Patterns and Their Association with Braak Staging, Cognition, and Onset of ad‐Dementia
Lowe, Val J. , Wiste, Heather J. , Fang, Ping , Josephs, Keith A. , Petersen, Ronald C. , Senjem, Matthew L. , Boeve, Bradley F. , Murray, Melissa E. , Kantarci, Kejal , Jones, David T. , Schwarz, Christopher G. , Knopman, David S. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2016.06.228 Get It

IC‐03‐04: Network‐Based TAU Deposition Patterns are Related to Functional Network Failure Largely Via Beta‐Amyloid Across The Alzheimer’s Spectrum
Lowe, Val J. , Wiste, Heather J. , Radford, Jonathan Graff, Petersen, Ronald C. , Jones, David T. , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.074 Get It

O4‐01‐01: Pattern of AV‐1451 Uptake in Dementia with Lewy Bodies and its Association with Amyloid‐Beta Deposition
Lowe, Val J. , Tosakulwong, Nirubol , Spychalla, Anthony J., Graff‐Radford, Jonathan , Petersen, Ronald C. , Kantarci, Kejal , Boeve, Bradley F. , Senjem, Matthew L. , Ferman, Tanis J. , Jones, David T. , Murray, Melissa E. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_6 | Pages: No page available

10.1016/j.jalz.2016.06.606 Get It

IC‐01‐01: Predictors of Regional TAU‐PET Uptake: Mayo Clinic Study of Aging
Lowe, Val J. , Wiste, Heather J. , Weigand, Stephen D. , Petersen, Ronald C. , Vemuri, Prashanthi , Senjem, Matthew L. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.061 Get It

P1‐262: Comparison of [18F]Flutametamol and [11C]PIB in Normal Young, Normal Elderly, and Alzheimer's Disease Subjects
Lowe, Val J. , Gunter, Jeffrey L. , Petersen, Ronald C. , Senjem, Matthew L. , Knopman, David S. , Lundt, Emily S. , Schwarz, Christopher G. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2016.06.1011 Get It

Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors
Shostrom, Valerie , Kumar, Sameera , Zhen, Weining, Hallemeier, Christopher L. , Holland, John , Harkenrider, Matthew M. , Iskhanian, Adrian S., Neboori, Hanmanth J., Attia, Albert, Lee, Percy , Alite, Fiori , Walker, Joshua M. , Stahl, John M. , Wang, Kyle , Bingham, Brian , Hadzitheodorou, C., Decker, Roy H. , McGarry, Ronald C., Simone, Charles B. , Verma, Vivek , Hallemeier, Christopher Leigh , Braunstein, Steve , Jabbour, Salma K , Simone, Charles B

Mayo Clinic

Cancer | October 14, 2016 | Volume: 123 | Issue: 4 | Pages: 688-696

10.1002/cncr.30375 | PMID 27741355 Get It

BACKGROUNDStereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early‐stage non–small cell lung cancer (NSCLC) measuring < 5 cm, but its use among patients with tumors measuring ≥5 cm is considerably less defined, with the existing literature limited to small, single‐institution reports. The current multi‐institutional study reported outcomes evaluating the largest such population reported to date.METHODSClinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring ≥5 cm without evidence of distant/lymph node metastasis who underwent SBRT using ≤5 fractions. Statistics included Kaplan‐Meier survival analyses and univariate/multivariate Cox proportional hazards models.RESULTSA total of 92 patients treated from 2004 through 2016 were analyzed from 12 institutions. The median follow‐up was 12 months (15 months in survivors). The median age and tumor size among the patients were 73 years (range, 50‐95 years) and 5.4 cm (range, 5.0‐7.5 cm), respectively. The median dose/fractionation was 50 Gray/5 fractions. The actuarial local control rates at 1 year and 2 years were 95.7% and 73.2%, respectively. The disease‐free survival rate was 72.1% and 53.5%, respectively, at 1 year and 2 years. The 1‐year and 2‐year disease‐specific survival rates were 95.5% and 78.6%, respectively. The median, 1‐year, and 2‐year overall survival rates were 21.4 months, 76.2%, and 46.4%, respectively. On multivariate analysis, lung cancer history and pre‐SBRT positron emission tomography maximum standardized uptake value were found to be associated with overall survival. Posttreatment failures were most commonly distant (33% of all disease recurrences), followed by local (26%) and those occurring elsewhere in the lung (23%). Three patients had isolated local failures. Grade 3 to 4 toxicities included 1 case (1%) and 4 cases (4%) of grade 3 dermatitis and radiation pneumonitis, respectively (toxicities were graded according to the Common Terminology Criteria for Adverse Events [version 4.0]). Grades 2 to 5 radiation pneumonitis occurred in 11% of patients. One patient with a tumor measuring 7.5 cm and a smoking history of 150 pack‐years died of radiation pneumonitis.CONCLUSIONSThe results of the current study, which is the largest study of patients with NSCLC measuring ≥5 cm reported to date, indicate that SBRT is a safe and efficacious option. Cancer 2017;123:688–696. © 2016 American Cancer Society.
Pipeline for uncoilable or failed aneurysms: 3-year follow-up results
Becske, Tibor , Potts, Matthew B. , Shapiro, Maksim , Kallmes, David F. , Brinjikji, Waleed , Saatçi, Işıl , McDougall, Cameron G. , Szikora, István , Moran, Christopher J. , Woo, Henry H. , Berez, Aaron L., Cher, Daniel , Siddiqui, Adnan H. , Albuquerque, Felipe C. , Berentei, Zsolt, Marosföi, Miklós , Cekirge, Saruhan H., Nelson, Peter K. , Lanzino, Giuseppe , Lopes, Demetrius K. , Levy, Elad I. , Fiorella, David , Siddiqui, Adnan H , Szikora, Istvan

Mayo Clinic

Journal of Neurosurgery | October 14, 2016 | Volume: 127 | Issue: 1 | Pages: 81-88

10.3171/2015.6.jns15311 | PMID 27739944 Get It

OBJECTIVEThe long-term effectiveness of endovascular treatment of large and giant wide-neck aneurysms using traditional endovascular techniques has been disappointing, with high recanalization and re-treatment rates. Flow diversion with the Pipeline Embolization Device (PED) has been recently used as a stand-alone therapy for complex aneurysms, showing significant improvement in effectiveness while demonstrating a similar safety profile to stent-supported coil treatment. However, relatively little is known about its long-term safety and effectiveness. Here the authors report on the 3-year safety and effectiveness of flow diversion with the PED in a prospective cohort of patients with large and giant internal carotid artery aneurysms enrolled in the Pipeline for Uncoilable or Failed Aneurysms (PUFS) trial.METHODSThe PUFS trial is a prospective study of 107 patients with 109 aneurysms treated with the PED. Primary effectiveness and safety end points were demonstrated based on independently monitored 180-day clinical and angiographic data. Patients were enrolled in a long-term follow-up protocol including 1-, 3-, and 5-year clinical and imaging follow-up. In this paper, the authors report the midstudy (3-year) effectiveness and safety data.RESULTSAt 3 years posttreatment, 74 subjects with 76 aneurysms underwent catheter angiography as required per protocol. Overall, complete angiographic aneurysm occlusion was observed in 71 of these 76 aneurysms (93.4% cure rate). Five aneurysms were re-treated, using either coils or additional PEDs, for failure to occlude, and 3 of these 5 were cured by the 3-year follow-up. Angiographic cure with one or two treatments of Pipeline embolization alone was therefore achieved in 92.1%. No recanalization of a previously completely occluded aneurysm was noted on the 3-year angiograms. There were 3 (2.6%) delayed device- or aneurysm-related serious adverse events, none of which led to permanent neurological sequelae. No major or minor late-onset hemorrhagic or ischemic cerebrovascular events or neurological deaths were observed in the 6-month through 3-year posttreatment period. Among 103 surviving patients, 85 underwent functional outcome assessment in which modified Rankin Scale scores of 0–1 were demonstrated in 80 subjects.CONCLUSIONSPipeline embolization is safe and effective in the treatment of complex large and giant aneurysms of the intracranial internal carotid artery. Unlike more traditional endovascular treatments, flow diversion results in progressive vascular remodeling that leads to complete aneurysm obliteration over longer-term follow-up without delayed aneurysm recanalization and/or growth.Clinical trial registration no.: NCT00777088 (clinicaltrials.gov)